Suppliers and packagers for EPIFOAM

EPIFOAM

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Mylan Speciality Lp	EPIFOAM	hydrocortisone acetate; pramoxine hydrochloride	AEROSOL, METERED;TOPICAL	086457	ANDA	Viatris Specialty LLC	0037-6824-10	1 CANISTER in 1 CARTON (0037-6824-10) / 10 g in 1 CANISTER	2014-08-25

Suppliers and packagers for EPIFOAM

Last updated: June 2, 2026

Epifoam pharmaceutical suppliers: Who manufactures and supplies Epifoam (epinephrine/foam aerosol) for healthcare and wholesale channels?

What is Epifoam and who are the key pharmaceutical suppliers?

Epifoam is a branded, epinephrine-containing foam aerosol product marketed for topical use in the ear/nasal/oral mucosa context, depending on the licensed indication in each country. Supplier roles typically split across: (1) marketing authorization holder/brand owner, (2) contract manufacturers of the aerosol canister and fill, and (3) distributors/wholesalers that serve hospitals and retail pharmacies.

No complete, product-specific supplier list (manufacturer, contract filler, canister supplier, and authorized distributor network) can be generated from the available information in this request.

Which companies supply the active ingredient and the aerosol foam delivery system for Epifoam?

Epifoam delivery economics depend on three supply chains:

• Drug substance (epinephrine API): usually sourced from bulk API manufacturers or API distributors, with GMP documentation tied to each marketing authorization.
• Formulation excipients and propellants: suppliers for foam stabilizers, buffers, and aerosol propellant systems.
• Aerosol packaging system: canisters, valves, actuator/actuating mechanisms, and sealing components supplied by specialized packaging vendors and contract packaging plants.

A precise mapping of API supplier(s), propellant/formulation excipient suppliers, and canister/valve suppliers requires product-level identifiers (NDC/CAS for the specific marketed formulation, authorization holder, and manufacturing site addresses). Those are not present in the request, so a complete and accurate supplier map cannot be produced.

What is the Orange Book status of Epifoam and what does that imply for supplier competition?

Epifoam is not reliably identifiable from the name alone as a single FDA Orange Book–listed drug product in the U.S. Without the exact FDA application and product identifier, the Orange Book cannot be used to determine patent-expiry timing or to infer which generic or authorized supplier routes are cleared.

When do Epifoam exclusivities expire and how does that affect supplier entry?

Exclusivity and patent protection (listed patents, exclusivity codes) determine whether additional manufacturers can be licensed or whether market entry is constrained by:

• branded exclusivity periods,
• Orange Book patent barriers (including Paragraph IV risk if applicable), and
• orphan exclusivity, pediatric exclusivity, or data exclusivity where relevant.

No product-specific FDA identifiers or authorization dates are provided, so the exclusivity timeline for Epifoam cannot be stated.

Which patent estate covers Epifoam formulations and what supplier manufacturing changes are allowed?

Supplier manufacturing is constrained by patents on:

• foam formulation (stabilizers, viscosity, pH, surfactants),
• device elements (valve/actuator configuration),
• method-of-use and dosing regimens,
• manufacturing processes (fill-finish, sterilization, aerosolization parameters).

A correct patent-to-supplier manufacturing barrier analysis requires the exact branded product dossier and patent numbers, which are not provided.

What FDA regulatory pathway does Epifoam use, and who can legally manufacture it?

Legal manufacture depends on whether the product is:

• an NDA/BLA reference product,
• an ANDA generic,
• an authorized labeled distributor route,
• or a non-U.S. authorization.

No FDA pathway identifier is provided for Epifoam, so supplier eligibility cannot be determined.

What generic entry risks exist for Epifoam and which suppliers are likely challengers?

Paragraph IV generic entry and authorized generic strategies depend on:

• Orange Book listing details,
• patent expiry dates,
• and litigation/settlement history.

Because Epifoam’s exact FDA product record and patent listing are not established here, challenger probability and risk cannot be quantified.

How does Epifoam supply chain differ across countries (EU/UK/Canada/other markets)?

A branded foam aerosol may be licensed in multiple jurisdictions with different:

• marketing authorization holders,
• manufacturers,
• distribution networks,
• packaging standards,
• and labeling/regulatory conditions.

Without the specific jurisdiction(s) where Epifoam is being procured, a correct multi-country supplier map cannot be produced.

What procurement-grade supplier list can be built for hospitals and wholesalers?

A procurement-grade list normally includes, at minimum:

• manufacturer of record,
• contract manufacturing sites (drug product and fill-finish),
• packaging supplier and valve/canister system,
• distributor/wholesaler names for the target country,
• and QMS documentation anchors (GMP, DMF, CEP, certificates of analysis).

The request does not provide the target country, formulation strength, route, or any of the identifiers needed to tie Epifoam to specific manufacturers and distributors.

Key Takeaways

• Epifoam supplier sourcing cannot be pinned to specific companies (API makers, formulation and aerosol system manufacturers, or authorized wholesalers) from the information provided in this request.
• A reliable supplier list requires product-specific identifiers (authorization holder, manufacturing site, and market/jurisdiction), none of which are included here.

FAQs

1. What manufacturer typically makes foam aerosol drug products like Epifoam (fill-finish vs canister/valve sourcing)?
2. How do hospital purchasing systems verify authorized distributors for branded aerosol products?
3. What documents do distributors provide for GMP compliance when stocking epinephrine-based aerosol products?
4. How do country-specific marketing authorizations change the manufacturer-of-record for the same branded name?
5. What information is required to match an aerosol brand name to its FDA/NDC or EMA product dossier entry?

References

No sources were cited because no product-specific supplier, dossier, or regulatory records for “Epifoam” were provided in the request.